Navigation Links
Tetraphase Pharmaceuticals Completes Series B Financing to Support the Advancement of Novel Antibiotic Drug Candidates
Date:10/6/2009

WATERTOWN, Mass., Oct. 6 /PRNewswire/ -- Tetraphase Pharmaceuticals Inc. announced today that it has closed the first tranche of its $25 million Series B financing to support the advancement of several novel and potent antibiotic drug candidates. This Series B Financing and first tranche of $10 million was funded by existing investors -- Mediphase Venture Partners, CMEA Ventures, Fidelity Biosciences, Flagship Ventures and Skyline Ventures.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090910/NE72856LOGO )

Tetraphase Pharmaceuticals was established in August 2006 to advance and commercialize the ground-breaking synthetic chemistry platform developed by internationally recognized chemist, Dr. Andrew Myers of Harvard University. This proprietary platform overcomes a key barrier to discovering unprecedented classes of antibiotics and other drugs by enabling for the first time their total synthesis from basic building blocks. The initial focus of the company is on the discovery of novel antibiotics to treat drug-resistant infections.

"This is an exciting time for Tetraphase, as we move our lead compound into the clinic and advance our pipeline of novel and potent antibiotic drug candidates," said Guy Macdonald, President and Chief Executive Officer.

About Tetraphase Pharmaceuticals Inc.

Tetraphase Pharmaceuticals is capitalizing on breakthrough synthetic chemistry technology for drug discovery and development based on a process developed by world leading organic chemist Dr. Andrew Myers of Harvard University. This enabling advance in chemistry provides the company with a broad-range of commercial opportunities across a number of significant disease categories.

SOURCE Tetraphase Pharmaceuticals Inc.


'/>"/>
SOURCE Tetraphase Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Merz Pharmaceuticals Announces Phase III Data for NT 201 in Post-stroke Upper Limb Spasticity
2. Access Pharmaceuticals Signs eMarketing Agreement With iMedicor For MuGard(TM)
3. Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
4. Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux
5. ISTA Pharmaceuticals Announces Conference Call and Webcast of Third Quarter 2009 Financial Results
6. Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
7. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
8. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
9. Merriman Curhan Ford Acted as Financial Advisor to TorreyPines Therapeutics, Inc. in the Completed Merger With Raptor Pharmaceuticals Corp.
10. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
11. Fovea Pharmaceuticals to be Acquired by sanofi-aventis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... DIEGO , Dec. 22, 2014  Pfenex Inc. ... Pfenex,s recombinant anthrax vaccine, has been filed and is ... funding provided by the Department of Health and Human ... Authority (BARDA). "We are extremely pleased to ... vaccine, Px563L.  This represents a significant milestone in our ...
(Date:12/22/2014)... -- TWi Biotechnology, Inc., today announced that it ... Biotechnology,s lead drug candidate, from The State Intellectual ... for patent application numbered 201180018154.8.  This patent includes ... for treatment of type II diabetes.  The patent ... for type II diabetes, and provides a protection ...
(Date:12/19/2014)... , December 19, 2014 TODAY, ... in the World announced the appointment of Peter ... Vonsée, as Chief Channels and Partner Officer. ... 2004 through to its acquisition by Oracle in 2011. ... at Geneva and subsequently Convergys, ...
Breaking Medicine Technology:Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4
... Aggregate Benefit over Placebo Larger at One Year ... June 11, 2007,/PRNewswire-FirstCall/ -- Medivation, Inc. today announced ... double-blind,placebo-controlled Phase 2 study in mild-to- moderate Alzheimer's,disease ... 12 months. Importantly, on every endpoint studied, the ...
... 2007 /PRNewswire/ -- GlaxoSmithKline,plc announced results from ... investigational non-peptide oral platelet growth,factor, PROMACTA(R) (eltrombopag ... at 50-75mg once daily resulted in a,statistically ... bleeding in adult patients with chronic idiopathic,thrombocytopenic ...
Cached Medicine Technology:Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 2Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 3Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 4Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 5Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 6Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 2Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 3Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 4Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 5Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 6
(Date:12/22/2014)... Fad diets have been around forever ... most fad diets have hung around so long is that ... is that, as the body becomes accustomed to new eating ... to reset the metabolism to return the body to fast ... all-inclusive diet plans that are medically supervised throughout. ...
(Date:12/22/2014)... Sagacious Consultants, the premier full-service Epic consulting company, ... ad hoc report writing service to meet the high ... for an annual subscription and get a fixed number ... discounted hourly rate. , Customers can choose from ... rate. Subscription hours are contracted in 25 hour increments. ...
(Date:12/22/2014)... On December 22, 2014, My Positive Perspective ... for an episode to celebrate Christmas. At the beginning ... so important to you that we all appreciate and ... should respect who Jesus was. I think sometimes we ... That means that on Jesus’ birthday we remember that ...
(Date:12/22/2014)... 2014 International efforts to ... epidemic are receiving further support from recent ... organizations (NGOs) and other charitable organizations. While ... emergency responders, patients and others can immediately ... CmTP MediDefense system , which includes ...
(Date:12/22/2014)... SUNDAY, Dec. 21, 2014 (HealthDay News) -- A new ... cow disease" in deer might also protect livestock and ... The vaccine appears to help prevent deer from becoming ... wasting disease, according to the report in the Dec. ... Chronic wasting disease is caused by mysterious infectious particles ...
Breaking Medicine News(10 mins):Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 2Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 3Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 4Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:My Positive Perspective Celebrates Christmas With an Event to Celebrate the Birthday of Jesus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Vaccine for Deer Against 'Mad Cow'-Like Illness Shows Promise 2
... Gentiva Health Services, Inc. (Nasdaq: GTIV ), a leading ... to present at the Jefferies 3rd Annual Healthcare Conference in New ... 2009. , , The presentations will be available to ... accessed by visiting http://investors.gentiva.com/events.cfm . Visitors ...
... ... New hope for a much needed new approach for tackling Alzheimer,s disease ... in Philadelphia. At the inaugural Targeting Alzheimer,s with Novel Therapeutics conference, ... Edward Tobinick MD, Director of the Institute for Neurological Research, a private ...
... Men Fly off the Shelves for Father,s Day , , ... for chronic lower back pain may lie in a $59.99 biomechanically-engineered ... be the turning point for the sixty million adults who reported ... shoe many claim to be a medical breakthrough is now available ...
... Inc. a technology and services company focused on global eClinical solutions ... 45th DIA Annual Meeting to be held later this month in ... well as a number of exciting new features and functionality in ... , Reaffirming our ...
... More Efficient Operation for Gateway Healthcare , , ... announced today that it is addressing the ... with the unique, next generation voice product, Cox ... moved its telecommunications services from a competitive provider to ...
... Over Half a Million Varicose Vein Patients Treated with VNUS Closure ... VNUS(R) Medical Technologies, Inc. (Nasdaq: VNUS ), a worldwide ... venous reflux disease , the underlying cause of ... week, it estimates the number of patients treated with the VNUS ...
Cached Medicine News:Health News:Gentiva(R) Health Services to Present at Jefferies 3rd Annual Healthcare Conference 2Health News:Gentiva(R) Health Services to Present at Jefferies 3rd Annual Healthcare Conference 3Health News:New Immune Approach for Treatment of Alzheimer's Disease 2Health News:New Immune Approach for Treatment of Alzheimer's Disease 3Health News:New Immune Approach for Treatment of Alzheimer's Disease 4Health News:One of Women's Best Kept Secrets is Now Available in the Men's Department 2Health News:DATATRAK Announces New Products and Features at DIA San Diego 2Health News:DATATRAK Announces New Products and Features at DIA San Diego 3Health News:DATATRAK Announces New Products and Features at DIA San Diego 4Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 2Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 3Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 4Health News:A Milestone of Opportunity for VNUS Medical Technologies 2Health News:A Milestone of Opportunity for VNUS Medical Technologies 3
Bravo Vacuum Pump. Complete with tubing....
Stand with buffer tubes for calibration of Bravo pH capsule....
... lower esophhageal sphincter (LES) can ... a separate manometry system. pH ... identification accessory kit and Digitrapper ... locate the LES. The kit ...
pH Calibration Stand with two Sealable Buffer Tubes 1 set....
Medicine Products: